Erasca Q2 net loss $44.1M; ERAS-0015 57% uORR in PDAC; raises $632M

Erasca, Inc.

Q2 2026 net loss $44.1M ($0.14/sh) vs $33.9M ($0.12/sh) in Q2 2025; R&D expense $35.9M vs $21.2M.
Cash $384.3M at June 30, 2026; July upsized offering raised ~$632.5M gross, Jan 2026 offering ~$258.8M.
ERAS-0015 at 32mg QD showed 57% uORR8wk in 2L+ KRAS G12X PDAC; no DLTs, no tx-related discontinuations, 100% median dose intensity.
Plans for three registration-enabling trials: 2L+ NSCLC (H1 2027), 1L PDAC (2027), RASm NSCLC (H2 2027-H1 2028).
Appointed Charles Fuchs as president of R&D and David Chonzi as SVP global pharmacovigilance in August 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.